Key Points
- David James Lennon sold 63,945 Whitehawk shares on April 8 at an average price of $3.40 for $217,413, lowering his stake by 10.71% to 533,122 shares; the sale was disclosed to the SEC and made to cover tax withholding from vesting equity awards.
- WHWK opened at $3.41 (market cap ~$160.95M, P/E 7.26) with a 12‑month range of $1.39–$4.48; the company recently beat quarterly EPS estimates (‑$0.34 vs. consensus ‑$0.55) and analysts' consensus is a "Hold" with a $6.50 target.
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) CEO David James Lennon sold 63,945 shares of the stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $3.40, for a total transaction of $217,413.00. Following the sale, the chief executive officer directly owned 533,122 shares of the company's stock, valued at $1,812,614.80. The trade was a 10.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
David James Lennon also recently made the following trade(s):
- On Tuesday, April 7th, David James Lennon sold 94,087 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.43, for a total transaction of $322,718.41.
- On Monday, April 6th, David James Lennon sold 102,395 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.51, for a total transaction of $359,406.45.
- On Thursday, April 2nd, David James Lennon sold 26,858 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.48, for a total transaction of $93,465.84.
- On Monday, March 2nd, David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.31, for a total transaction of $16,881.00.
Whitehawk Therapeutics Stock Down 0.6%
Shares of WHWK opened at $3.41 on Thursday. The stock has a market capitalization of $160.95 million, a P/E ratio of 7.26 and a beta of 0.57. The firm has a fifty day simple moving average of $3.32 and a two-hundred day simple moving average of $2.69. Whitehawk Therapeutics, Inc. has a twelve month low of $1.39 and a twelve month high of $4.48.
Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.21.
Hedge Funds Weigh In On Whitehawk Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the business. Quadrature Capital Ltd purchased a new position in shares of Whitehawk Therapeutics in the fourth quarter worth approximately $28,000. ABG Innovation Capital Partners III GP Ltd purchased a new position in shares of Whitehawk Therapeutics in the third quarter worth approximately $51,000. Dimensional Fund Advisors LP purchased a new position in shares of Whitehawk Therapeutics in the third quarter worth approximately $84,000. Squarepoint Ops LLC purchased a new position in shares of Whitehawk Therapeutics in the third quarter worth approximately $159,000. Finally, Marshall Wace LLP bought a new stake in Whitehawk Therapeutics during the 4th quarter worth approximately $164,000. Hedge funds and other institutional investors own 52.08% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently commented on WHWK shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Whitehawk Therapeutics in a report on Friday, March 27th. Oppenheimer started coverage on shares of Whitehawk Therapeutics in a report on Thursday, February 5th. They set an "outperform" rating and a $6.00 price target on the stock. JonesTrading initiated coverage on shares of Whitehawk Therapeutics in a report on Monday, December 22nd. They set a "buy" rating and a $7.00 price target on the stock. Finally, Wall Street Zen raised shares of Whitehawk Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, March 21st. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $6.50.
Check Out Our Latest Report on WHWK
Whitehawk Therapeutics Company Profile
(
Get Free Report)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
